Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
Other equities research analysts also recently issued research reports about the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, October 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Friday, October 2nd. Zacks Research lowered shares of Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Finally, Needham & Company LLC reduced their target price on Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $13.57.
Read Our Latest Stock Analysis on BCYC
Bicycle Therapeutics Stock Performance
Shares of NASDAQ:BCYC opened at $3.37 on Friday. Bicycle Therapeutics has a 52-week low of $3.26 and a 52-week high of $7.83. The stock’s fifty day simple moving average is $3.70 and its 200-day simple moving average is $4.42.
Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.25. The firm had revenue of $34.06 million during the quarter, compared to the consensus estimate of $12.22 million. Bicycle Therapeutics had a negative net margin of 169.75% and a negative return on equity of 26.02%. On average, equities research analysts anticipate that Bicycle Therapeutics will post -2.11 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of BCYC. GAMMA Investing LLC increased its holdings in Bicycle Therapeutics by 512.9% during the 2nd quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock worth $33,000 after purchasing an additional 6,447 shares during the last quarter. Portland Investment Counsel Inc. bought a new position in Bicycle Therapeutics during the 2nd quarter valued at $64,000. Royal Bank of Canada boosted its stake in Bicycle Therapeutics by 35.5% during the 1st quarter. Royal Bank of Canada now owns 14,470 shares of the company’s stock valued at $67,000 after acquiring an additional 3,788 shares during the last quarter. 49 Wealth Management LLC bought a new position in Bicycle Therapeutics during the 3rd quarter valued at $84,000. Finally, Vontobel Holding Ltd. grew its holdings in Bicycle Therapeutics by 15.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 23,000 shares of the company’s stock worth $85,000 after acquiring an additional 3,000 shares in the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts. The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access.
Read More
- Five stocks we like better than Bicycle Therapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
